Assessment of quality and pre-clinical efficacy of a newly developed polyvalent antivenom against the medically important snakes of Sri Lanka

Aparup Patra¹, Bhargab Kalita¹, Milind V. Khadilkar², Nitin C. Salvi², Pravin V. Shelke² & Ashis K. Mukherjee¹,3

Snake envenomation is a severe problem in Sri Lanka (SL) and Indian polyvalent antivenom (PAV) is mostly used for treating snakebite albeit due to geographical variation in venom composition, Indian PAV shows poor efficacy in neutralizing the lethality and toxicity of venom from the same species of snakes in SL. Therefore, the quality and in vivo venom neutralization potency of a country-specific PAV produced against the venom of the five most medically important snakes of SL (Daboia russelii, Echis carinatus, Hypnale hypnale, Naja naja, Bungarus caeruleus) was assessed. LC-MS/MS analysis of two batches of PAV showed the presence of 88.7–97.2% IgG and traces of other plasma proteins. The tested PAVs contained minor amounts of undigested IgG and F(ab)2 aggregates, showed complement activation, were devoid of IgE, endotoxin, and content of preservative was below the threshold level. Immunological cross-reactivity and in vitro neutralization of enzymatic activities, pharmacological properties demonstrated superior efficacy of SL PAV compared to Indian PAV against SL snake venoms. The in vivo neutralization study showed that the tested PAVs are potent to neutralize the lethality and venom-induced toxicity of SL snake venoms. Therefore, our study suggests that introduction of SL-specific PAV will improve snakebite management in SL.

Snakebite is a severe problem in the Indian subcontinent and has been declared as a neglected tropical disease by the World Health Organization (WHO). Sri Lanka (SL), a small island of South Asia located in the Indian Ocean, reports approximately 30,000 snake envenomations that result in 450 deaths per year¹,². SL is the home for 96 terrestrial and 15 aquatic species of snakes³, with the hump-nosed viper (Hypnale hypnale), Russell’s viper (Daboia russelii), the Indian common krait (Bungarus caeruleus), the Indian cobra (Naja naja), and the saw-scaled viper (Echis carinatus) are regarded as the most dangerous species of venomous snakes since they account for most of the snakebite fatalities in SL⁴.

Snakebite is a medical emergency that requires immediate medical treatment; otherwise, it may result in death and/or permanent morbidity. The only effective treatment against snakebite is intravenous administration of polyvalent antivenom (PAV). In SL, the most widely used antivenom is the Indian PAV raised against the ‘big four’ venomous snakes of India (D. russelii, N. naja, E. carinatus, and B. caeruleus)⁵. Currently, important concerns are being raised about using Indian PAV for the treatment of snakebites in SL. The primary objection is that due to geographical variations, the composition of Indian snake venoms used for immunizing and raising equine antibodies are different from the venom compositions of the same species of snakes in SL⁶–⁹. Consequently, Indian PAV is found to be less efficient in neutralizing the lethality and toxicity of venoms of SL snakes and additional doses of PAV are necessary for treating snakebite patients in SL. This increases the risk of adverse serum reactions in the antivenom-treated patients¹⁰,¹¹ and unnecessarily increases the cost of treatment. The Indian PAV’s are also limited by its absence of antibody against Hypnale hypnale venom (HHV), which is responsible for the most envenomation in SL⁴. Neutralizing HHV is therefore exclusively dependent on the antibodies raised against the

¹Microbial Biotechnology and Protein Research Laboratory, Department of Molecular Biology and Biotechnology, School of Science, Tezpur University, Tezpur, Assam 784028, India. ²Premium Serums and Vaccines Pvt. Ltd, Narayangao, Pune, Maharashtra 410504, India. ³Institute of Advanced Study in Science and Technology, Vigyan Path, Garchuk, Paschim Boragaon, Guwahati, Assam 781035, India. *email: akm@tezu.ernet.in
venom toxins of the same Viperidae family of snakes (D. russelli and E. carinatus), and consequently, the PAV that is in current use is less efficient for treating H. hypnale envenomation in SL. Further, the supply of PAV from India is not sufficient to fulfill the annual requirements for antivenom in SL, which is causing a shortage of antivenom in this country. These issues can be addressed by developing SL-specific PAV raised against snake venoms of SL origin, which is urgently needed for effective snakebite treatment in this country.

Recently, the pre-clinical efficacy of a newly developed SL venom-specific antivenom was reported, however, a similar initiative is still desired to fulfill the demand for PAV to treat the large number of snakebites in SL. In this study, we characterized a newly developed country-specific PAV designated as SL PAV against H. hypnale venom (HHV), D. russelli venom (DRV), N. naja venom (NNV), E. carinatus venom (ECV), and B. caeruleus venom (BCV) sourced from SL. Notably, the World Health Organization (WHO) Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins published in 2016, recommended that standard in vitro laboratory tests be conducted to ascertain the purity, quality, and safety of the antivenom as the essential quality control before the pre-clinical assessment of PAV. Therefore, in addition to assessing the in vivo neutralization potency of SL snake venoms-induced lethality and toxicity by SL PAV, we also determined the physicochemical properties, purity of active substance, load of preservatives and neutralization of some enzymatic activity and pharmacological properties of SL snake venoms by this newly developed SL PAV by in vitro laboratory assessments. Our study has shown that some pharmacological properties of SL snake venoms and their enzymatic activity were neutralized by the newly developed SL PAV to a greater extent when compared to Indian PAVs that are being used for snakebite treatment in SL. The assessment indicated the enhancement of efficacy and potency of the former PAV.

**Results and discussion**

**Preliminary physicochemical analysis of SL PAV.** Examining the physicochemical properties of a drug is a preliminary but an important aspect for assessing its quality. Both vials of lyophilized PAV appeared as homogenous white colored powder, with fragment cake-like structure (Supplementary Fig. S1); however, batch 1 (B1) showed more shrinkage than the batch 2 (B2). These cake-like structure may be formed due to mechanical damage and may have impact on reconstitution time and turbidity but the cake-like structure of the lyophilized powder does not affect their biological activity (venom neutralization potency). The SL PAV was found to be completely dissolved within 5–6 min in 10 mL of sterile deionized water and no insoluble material was observed. This result suggests good water solubility of lyophilized powder. The turbidity measures the cloudiness of a solution; therefore, low turbidity of a solution indicates that solute (PAV in this case) is well mixed with the solvent (sterile deionized water). Consequently, WHO has suggested for quantitative measurement of the turbidity of antivenoms solution by using a turbidimeter; albeit, no standard value of turbidity is fixed. The turbidity of the SL PAV B1 and B2 was found to be 15.3 ± 0.6 and 11.1 ± 0.8 nephelometric turbidity units (NTUs), respectively indicating they accomplish the WHO guidelines. The pH of the reconstituted SL PAV should be around 7.0 ± 0.5. The aqueous solutions of the two batches of SL PAVs had pH values between 6.95 ± 0.2 and 6.89 ± 0.3, which is quite close to the standard set by the WHO.

In developing countries, snakebite is regarded as an occupational health hazard for rural people and a socioeconomic problem, and therefore, PAV should be available at rural health centers. The lyophilized PAV is more suitable than liquid antivenom for long-term storage (2–3 years) without requiring refrigeration at rural hospitals. The moisture content of the lyophilized product reduces the shelf-life either by denaturing the product or by aggregating F(ab’), molecules that causes a significant reduction in its venom neutralization potency. For the two batches of the tested SL PAVs, the moisture content was determined to be in the safe range (< 3%)..

**Tandem mass spectrometry and size exclusion chromatography analyses to determine the purity of the active substances of PAV preparations.** The antivenoms are manufactured as undigested immunoglobulin G (IgG) molecules or fragmented F(ab’), molecules (pepsin digested IgG to remove its Fc region). The Indian PAVs and the newly developed SL PAV contain F(ab’), and therefore theoretically believed to show less serum reactions in treated patients, however, detailed clinical studies are warranted to confirm the advantages of pepsin digested IgG. The neutralization potency and efficacy of IgG and F(ab’), are not significantly different; however, they have different pharmacokinetic profiles. Notably, F(ab’), has certain advantages over the parent IgG molecule, for example, easier access to extravascular tissue and rapid elimination from the blood, higher distribution rate and neutralization potency for low molecular mass venom toxins, particularly against the venoms of Elapidae family of snakes comprised of relatively higher proportion of low molecular mass toxins.

One of the key steps in the antivenom manufacturing process is the caprylic acid treatment of horse hyperimmunized serum to precipitate the non-IgG proteins. Because experimental error or insufficient quality control during the preparation might lead to incomplete or partial digestion of IgG proteins or contamination of F(ab’), with the undesirable non-IgG proteins of serum, the SL PAV was analyzed by LC–MS/MS to determine the presence of any contaminating serum proteins. According to WHO guidelines, total protein concentration of PAV solution should not exceed 10 g/dL. The protein concentration of the aqueous solution of B1 and B2 of SL PAV was found to be 7.3 ± 0.2 and 7.5 ± 0.4 g/dL, respectively indicating they accomplish the WHO guidelines. The LC–MS/MS analysis of the SL PAV batches against E. carus (taxid 9796) proteins in the UniProt database using emPAI-based label-free quantification method showed that the percent content of immunoglobulin molecule [IgG and/or F(ab’),] in B1 and B2 of SL PAV was 88.8% and 97.2%, respectively, and the remaining contaminating proteins were fibrinectin, fibrinogen, haptoglobin, serum albumin, alpha-2 macroglobulin, albumin, prothrombin, and plasminogen. The above mentioned contamination proteins are also found to be present however to a varying extent in other commercial PAVs suggesting improved...
cost-effective method for the isolation of IgG and/or F(ab')₂ is required. As per the recommendation of WHO (2016)¹⁴, the albumin concentration should not be more than 1% of total protein content of antivenom. In the present study, the albumin content of B2 is found within this limit however, this content is slightly higher in B1 (Fig. 1). Notably, ion-exchange chromatography of hyper-immunized serum after caprylic acid precipitation has been suggested to significantly reduce the contaminating proteins in PAV preparations²⁹. However, adopting this process for antivenom manufacturing, which is not required according to the WHO guidelines, would increase the production cost of PAV and make it less affordable in the developing nations.

The purity of the active substances [F(ab')₂] of both batches of SL PAV was assessed by gel filtration chromatography (GFC) followed by SDS-PAGE analysis of the gel filtration protein peaks. The gel filtration chromatogram of each batch of SL PAV was resolved into a major broad protein peak (GF1) that eluted around fractions 42–68 mL (Supplementary Fig. S2). The percent protein content of GF1 in the two different batches of SL PAV was determined to be in the range from 93.7 to 96.8% (Supplementary Fig. S2). When compared to the standard chromatograms of purified F(ab')₂ and horse IgG, the GF1 fraction of SL PAV batches 1 and 2 were found to contain F(ab')₂ and/or IgG (Supplementary Fig. S2); however, minor quantities of other contaminating serum proteins with a molecular mass close to that of IgG or F(ab')₂ may also be present in this fraction that can only be determined by the LC–MS/MS analysis of the GF fractions.

The SDS-PAGE analyses of both batches of SL PAV and their GF peak 1 under non-reduced and reduced conditions are shown in Fig. 2a,b. Under the non-reduced conditions, the PAV samples and their GF peaks showed a smeared band at molecular mass ranging from 100 to 170 kDa (Fig. 2a) which is due to undigested IgG and/or aggregates of IgG and/or F(ab')₂. In reduced condition, affinity-purified horse F(ab')₂ resolved with a single band ~ 25 kDa as both the heavy and light chains are of same molecular mass (25 kDa); however, the tested PAVs showed a major broad band at ~ 25 kDa along with a light-stained band at ~ 35 kDa suggesting some of the F(ab')₂ molecules were incompletely digested in the PAV preparation (also see below) (Fig. 2b). This findings were also similar to the previously characterized F(ab')₂ antivenom from different manufacturers¹⁶,¹⁹,²⁶,²⁸,³⁰. Therefore, the pepsin digestion protocol should be properly followed and special attention should be given to avoid incomplete digestion of IgG molecules.

The densitometry analysis of the SDS-PAGE protein bands of both batches of SL PAV and their respective GF peak (GF1) suggested that they contained minor amounts of undigested IgG (10.0–12.2%) along with F(ab')₂ molecules (87.8–89.9%) (Fig. 2a-d). The other minor faint protein bands observed in SDS-PAGE may correspond to the other contaminating serum proteins identified by LC–MS/MS analysis. The SDS-PAGE analysis of the two batches of SL PAVs showed a minor amount of aggregate (4.5 and 5% for B1 and B2, respectively) content (Fig. 2e). This result corroborates the characterization of SABU Indonesian antivenom that showed 7.3% of the F(ab')₂ dimer and aggregates in the antivenom preparation³⁰; however some of the Indian PAVs showed more aggregate (10–30%) content²⁸. The protein aggregates are responsible for early adverse reactions¹⁴, though customization and refinements in the antivenom production protocol can lead to pure, aggregate-free F(ab')₂ antivenom³¹.

**Characterization of the safety profiles of SL PAV.** The presence of incomplete or partially digested IgG in SL PAV was determined by enzyme-linked immunosorbent assay (ELISA) and western blot analyses using anti-Fc antibody. The ELISA and immunoblot analysis of the two batches of SL PAV showed 13.9 ± 0.6% and 12.1 ± 0.5% (B1 and B2, respectively) of undigested IgG content (Fig. 3). This result is corroborated by the data from the densitometry analysis of SDS-PAGE bands of crude SL PAV (Fig. 2c). Although the venom neutralization potency is the same for IgG and F(ab')₂, the latter product shows less complement activation¹⁴,³².
Figure 2. SDS-PAGE analysis of the two batches of SL PAV and their gel filtration fractions under (a) non-reduced, and (b) reduced conditions. Lanes M, protein molecular markers; lanes 1 and 3 represent PAV of batch B1 and B2, respectively; lanes 2 and 4 represent gel filtration peak GF1 of B1 and B2 of PAV, respectively; lanes 5 and 6 represent purified horse IgG and F(ab’)2 fragment, respectively. Determination of percent composition of IgG and F(ab’)2 by densitometry analysis; (c) two batches of SL PAV and (d) their gel filtration fractions (GF1). (e) Analysis of F(ab’)2 and/or IgG aggregates in the PAVs (B1 and B2) by SDS-PAGE analysis. Values are mean ± SD for triplicate determinations. No significant difference was observed between the two batches of SL PAV (p > 0.05).

Figure 3. Determination of Fc content of IgG by Western blot analysis. Immunoblot analysis of the SL PAV B1, B2 and purified horse IgG was done by using anti horse IgG HRP conjugated Fc region-specific antibody. M represents protein molecular mass marker and B1 and B2 represent batch 1 and batch 2 of PAV, respectively. The primary antibody for both the analyses was raised against Fc region of IgG.
While partially digested IgG was present in the PAV in this study, further precision is recommended in this step to improve the product quality.

The complement activation property of antivenom is primarily due to the Fc portion of the undigested IgG. However, as already discussed, removal of Fc portion of IgG by pepsin digestion does not guarantee the elimination of early anaphylactic reactions (EARS) induced by complement activation. Studies have shown that, both IgG and F(αβ)₂, antivenoms showed higher complement activation when precipitated with ammonium sulphate salt compared to precipitation by caprylic acid. Nevertheless, IgG/F(αβ)₂ aggregates, an excess amount of preservative (cresol), and the hinge portion of the IgG can also contribute to complement activation in PAV-treated patients. The two batches of SL PAV showed complement activation in vitro with a CH50/mL value (%) of 61.6 ± 3.2, and 64.5 ± 2.9 and AP50/mL value (%) 69.1 ± 4.1 and 65.7 ± 3.9 for SL PAV B1 and B2, respectively. Antivenoms manufactured by Butantan Institute (São Paulo, Brazil) and Clodomiro Picado (San José, Costa Rica) were reported to have variable CH50/mL values (50–95%), which would account for variable degrees of complement activation in vitro. A recent study has shown the CH50/mL and AP50/mL values (%) of Indian PAVs in the range of 45 to 70% and 30 to 60%, respectively. Both the IgG and F(αβ)₂ molecules can activate the complement pathway, though the former compared to later showed higher complement activation in vitro. Noteworthy to mention, the WHO has not fixed any standard safe range for complement activation by antivenoms. The complement activation shown by SL PAV in this study was assessed only by in vitro analysis and this should be confirmed and validated by in vivo pre-clinical studies or clinical case studies from antivenom-treated patients.

IgA and IgE molecules can be co-separated with the IgG molecule during precipitation of IgG from hyperimmune plasma and have no role in neutralizing the venom toxin. Although no adverse effect of IgA has been reported, IgE contamination in antivenom preparations can induce a hypersensitivity reaction leading to anaphylactic shock in antivenom-treated patients. The two batches of SL PAV were found to contain IgA and IgE molecules can be co-separated with the IgG molecule during precipitation of IgG from hyperimmune plasma and have no role in neutralizing the venom toxin. Although no adverse effect of IgA has been reported, IgE contamination in antivenom preparations can induce a hypersensitivity reaction leading to anaphylactic shock in antivenom-treated patients. The two batches of SL PAV were found to contain IgA and IgE.

The sterility assessment of SL PAV showed that both batches were free of microbial contamination (Supplementary Fig. S5). During the processing of immunoglobulins of horse plasma, they may become contaminated with bacteria, and as a consequence, PAV can be contaminated with bacterial endotoxin. Depending upon the potency and quality of product, the doses of antivenom ranges from 20 to 120 mL and the maximum acceptable content of endotoxin in an antivenom preparation should be within a range of 2.9 to 17.5 EU/mL (endotoxin unit/mL or EU/mL) and above this level, a high risk exists for inducing pyrogenic reaction in antivenom-treated patients. The endotoxin load in the two batches of SL PAVs was determined to be within the range of 1.5–1.7 EU/mL, suggesting that they are safe (in terms of endotoxin contamination) to administer to snakebite patients.

Cresol is used as preservative for long-term storage of antivenoms; however, the cresol content in antivenom should not exceed 0.35% by weight (or 3.5 g/L). A high content of cresol in antivenoms has been reported to cause a hypersensitive reaction in patients. RP-HPLC analysis showed that the cresol content in the two batches of SL PAV was within the range of 0.18 to 0.23% (Supplementary Fig. S4a–c), which is significantly below the limit of allowed preservative in an antivenom preparation. Thus, these results advocate for the quality and safety of the newly developed SL PAV.

The number of vials of PAV required to cure a snakebite patient depends on the severity of the envenomation (amount of venom injected into the victim), efficacy of the antivenom, and sometimes repeated doses of PAV are administered over a period of 2–3 days. Therefore, to determine any possible deleterious effects of PAV, mammalian cells were challenged with a high dose (20 µg/mL or 2 mg/dL) of SL PAV and cytotoxicity, if present, was assessed up to 72 h post treatment. None of the tested mammalian cells showed cytotoxicity (Supplementary Fig. S8). Furthermore, both batches of PAV were devoid of direct or indirect hemolytic activity against mammalian erythrocytes (data not shown).

A summary of the physicochemical properties and safety profiles of the two batches of SL PAV is shown in Table 1.

Comparison of immunological cross-reactivity and neutralization of enzyme activity and pharmacological properties of SL snake venoms by Indian and SL PAV. For treating snakebite in SL, Indian PAV is mostly used, though its efficacy and neutralization potency towards SL snake venoms is of immense concern. Further, Indian PAV does not contain antibody against HHV, even though the largest number of snake bites in SL are from this species. Therefore, it would be essential to include HHV-specific antibodies in a PAV preparation for better protection against snakebite by this pit viper in SL. This long-standing requirement of clinicians can be fulfilled by the newly developed SL PAV. The superiority of the newly developed country-specific SL PAV over Indian PAV was demonstrated by ELISA and Western blot analyses, two important laboratory techniques for quantifying the venom-antivenom cross-reactivity. Although in vivo neutralization study of venom-induced lethality and toxicity is the gold standard for pre-clinical assessment of a PAV, however, prior to the in vivo pre-clinical assessment, the efficacy and potency of the antivenom can be assessed by determining the immunological cross-reactivity between venom and antivenom (by ELISA and immunoblotting techniques). The in vitro neutralization of selected enzymatic activities and pharmacological properties of venom samples can also be evaluated. The results of these tests can provide a clear understanding of the efficacy of antivenom. These assessments are highly recommended as they involve a minimal use of experimental animals and they are ethically acceptable.

The result of the ELISA showed that both batches of SL PAV (compared to Indian PAV) demonstrated significantly higher immuno-recognition of the SL snake venom samples; PAVs demonstrated the highest and lowest immuno-recognition against the venom of E. carinatus and B. caeruleus, respectively (Fig. 4). Further, the
### Table 1. Summary of the quality and safety assessment of SL PAV batch 1 and batch 2. Detailed methodologies are described in the text.

| Parameters (unit) | Testing method | Results | Regulatory requirement (WHO, 2016) |
|------------------|----------------|---------|-----------------------------------|
| Appearance       | Visual observation of colour, and physical appearance of the powder (in case of freeze-dried preparations) | White in colour and powder like appearance, more cake-like structure is observed | Compliance with the description of the marketing dossier |
| Residual moisture (freeze-dried preparations) (%) | Heat dying method | <3 | Less than 3% |
| Solubility (freeze-dried preparations) (min) | Addition of solvent and observation of time to reach solubility and of appearance | ~5 | ~5 | Product should be completely dissolved within 10 min |
| Turbidity (NTU) | By using a turbidimeter | 15.3 ± 0.6 | Solution should not be cloudy but threshold level is not mentioned in the guidelines |
| pH of solution | By using a potentiometer (pH meter) | 6.95 ± 0.2 | Specifications of Pharmacopoeias and regulatory agencies (generally neutral pH) |
| Total protein concentration (g/dL) | Lowry method | 7.3 ± 0.2 | Not more than 10 g/dL |
| Serum albumin content (%) | LC–MS/MS | 1.54 | Ideally should be within 1% |
| Test for pyrogen substances (EU/mL) | Limulus Amebocyte Lysate (LAL) test when validated and approved by national regulatory agency | 1.55 ± 0.07 | Accepted limits by the pharmacopeia in use |
| Sterility test (microbial cfu) | Filtration through membranes, neutralization (when preservatives are used), and addition to culture media (trypticase soy broth and thioglycolate) | No microbial growth | Absence of microbial growth |
| Concentration of preservative (g/L) | RP-HPLC-based method (cresol) | 0.4 ± 0.03 | Phenol: maximum 2.5 g/l |
| Complement activation (CH50/mL and AP50/mL) | Biochemical assay to determine CH50 and AP50 value for classical and alternative pathway, respectively | CH50/mL (%) – 61.6 ± 3.2 | Threshold level is not mentioned |
| Fc content of IgG (%) | Immunological assay (ELISA and immunoblotting) by using anti-Fc specific antibody | 13.9 ± 0.6 | Threshold level is not mentioned |

**Figure 4.** Determination of immunological cross-reactivity between two batches of SL PAV/Indian PAVs and SL snake venoms by ELISA. Values are mean ± SD for triplicate determinations. *Significance of difference between SL PAV B1 and B2 with respect to BSVL; †significance of difference between SL PAV B1 and B2 with respect to PSVPL; ‡significant difference between SL PAV B1 and B2 with respect to VINS, (p < 0.05).
two batches of SL PAV did not show any significant deviation (p > 0.05) in their immuno-recognition of venom samples. In addition, because Indian PAVs do not contain antibodies against HHV, their recognition towards HHV (compared to that of SL PAV) was extremely poor (Fig. 4). Though, a marginal recognition of *H. hypnale* by Indian PAVs suggests that these venom toxins may share sequence similarities with the homologous toxins from Indian *D. russelii* and *E. carinatus* venoms as they all belong to the Viperidae family of snakes6,44,45,49,54.

Several researchers have suggested that immunoblot analysis is an important in vitro laboratory test to determine the potency of PAV45,46,48,55. The results of immunoblot analysis were also in accordance with the ELISA results (Fig. 5a–g); SL ECV exhibited the best immuno-recognition compared to other venoms (Fig. 5a–g, Supplementary Figs. S9, S10, S11a,b). In our previous studies, we reported a poor immuno-recognition of low molecular mass (< 20 kDa) Indian snake venom proteins by commercial Indian PAV6,43–45,49–51. In this study, however, both batches of SL PAV (compared to Indian PAV) exhibited significantly higher immuno-recognition of low molecular mass proteins of SL snake venoms. Moreover, no batch to batch variations (among B1 and B2) were seen in the immuno-recognition properties of country-specific SL PAV (Fig. 5a–g).

Snake venom enzymes, particularly those from the Viperidae family of snakes, play a vital role in venom-induced toxicity and lethality6,47,56,57. Viperidae venoms are rich in enzymatic toxins like phospholipase A₂ (PLA₂), snake venom metalloprotease (SVMP), and snake venom serine protease (SVSP), which play an important role in the toxicity of venom45,47,56,61. Therefore, assessing the in vitro neutralization of catalytic activities and the pharmacological properties of these enzymes by commercial PAV is another important in vitro method for determining the efficacy of commercial antivenom.

The in vitro neutralization of some enzymatic activities and pharmacological properties of SL snake venoms by country-specific SL PAV, and Indian PAV was compared. The enzymatic activities exhibited by high molecular mass venom proteins (adenosine tri/di/mono phosphatase, l-amino acid oxidase, hyaluronidase, and

---

**Figure 5.** Immunoblot cross-reactivity of SL venoms. (a) SDS-PAGE images of SL venoms. (b–f) Western blot images of SL venoms against two batches (B1 and B2) of SL PAV, and Indian PAVs (BSVL, PSVPL, and VINS). (g) Densitometry analyses of immunoblots as shown in (b–f) Values are mean ± SD of duplicate determinations. *Significant difference between SL PAV B1 and B2 with respect to BSVL; †Significant difference between SL PAV B1 and B2 with respect to PSVPL; ‡Significant difference between SL PAV B1 and B2 with respect to VINS (p < 0.05). Same molecular marker (M) was used for all the blots. The Ponceau stained blot images are shown in supplementary Fig. S8. The full length unedited blot images are shown in supplementary Fig. S9.
contain cytotoxins in their venom which lead to significant tissue necrosis. In this case, the neutralization of \textit{Bungarus} and kraits (\textit{sp.}) induces a neurotoxic effect that is the primary cause of lethality; albeit, elapids also well neutralized. The enzymatic activity exhibited by HHV was better neutralized by SL PAV than by Indian protection to SL krait bite patients. Consequently, it may be anticipated that owing to containing antibodies against Elapidae family of snake venom in ICP PAV may not be ruled out; nevertheless, it cannot ensure full protection to SL krait bite patients. In another study, the average venom yields have been reported as same species of snakes in India have reported average venom yields of 330 mg, 22.7 mg, 200 mg and 6.25 mg for NNV, BCV, DRV and ECV, respectively. Thus, these two species of snakes show a wide range of pathophysiological effects such as myonecrosis, dermonecrosis, hemorrhage, edema, coagulopathies, bleeding in various organs, hemodynamic disturbances, and renal disturbances.

**Table 2.** Determination of lethality of SL venoms (LD\(_{50}\) value) and neutralization of lethality (ED\(_{50}\) value) of venom samples by two batches of SL PAV. Neutralization activity by PAV is expressed as mg venom neutralized per mL of antivenom. The venom stock (1 mg/mL) was used and injected in the mice at different dilution (1:8, 1:10, 1:12.5). The LD\(_{50}\) and ED\(_{50}\) values given below are means ± SD of five values.

| SL snake venom | LD\(_{50}\) value (µg/mouse) | ED\(_{50}\) value (mg/mL) | Dose 1 | Dose 2 |
|---------------|-----------------------------|--------------------------|--------|--------|
| Naja naja     | 20.33 ± 1.16                | 0.732 ± 0.04             | 0.687 ± 0.06 | 1400 ± 0.08 | 1500 ± 0.13 |
| Bungarus caeruleus | 1.50 ± 0.25            | 0.523 ± 0.03             | 0.556 ± 0.06 | 1900 ± 0.09 | 1800 ± 0.18 |
| Daboia russelli | 8.75 ± 0.30                | 0.786 ± 0.02             | 0.710 ± 0.04 | 1300 ± 0.04 | 1400 ± 0.08 |
| Echis carinatus | 10.85 ± 0.21              | 0.586 ± 0.03             | 0.586 ± 0.02 | 1700 ± 0.09 | 1700 ± 0.07 |
| Hypnale hypnale | 30.19 ± 1.90             | 0.725 ± 0.06             | 0.689 ± 0.05 | 1400 ± 0.12 | 1500 ± 0.11 |

SVMP) were better neutralized in comparison to low molecular mass venom toxins (e.g., PLA\(_2\)), though the neutralization potency of both batches of SL PAV was higher (p < 0.05) than that of Indian PAVs (Supplementary Fig. S12a–e). Poor neutralization of PLA\(_2\) activity is a major concern for venom-induced toxicity and lethality. Immunoblotting analysis showed that the SDS-PAGE protein band (~ 13–15 kDa) for PLA\(_2\) is immuno-recognized by the SL PAV; however, the catalytic site of PLA\(_2\) enzyme, may be due to its poor immunogenicity, is not well neutralized. The enzymatic activity exhibited by HHV was better neutralized by SL PAV than by Indian PAVs since the latter do not contain antibodies against this venom. This result shows a significant improvement in the immuno-recognition and in the neutralization of venom enzymes of SL snake venoms by country-specific SL PAV in comparison to Indian PAV developed against the Indian 'big four' snake venoms. In a nutshell, the in vitro laboratory tests provide convincing evidence for the significant improvement of the venom recognition property of the newly developed SL PAV, in comparison to Indian PAV.

**Evaluation of pre-clinical efficacy of country-specific SL PAV.** Assessing the neutralization of in vivo lethality and toxicity of snake venoms by commercial PAV is the gold standard for determining their efficacy and it is a crucial step in the clinical assessment of PAV. The in vivo venom neutralization potency of SL PAV is shown in Table 2. Recently, the pre-clinical efficacy of a newly developed SL snake venom-specific PAV (raised against SL snake venoms—DRV, ECV, HHV, and NNV) by Instituto Clodomiro Picado (ICP), Costa Rica, has been assessed. To the best of our knowledge, this PAV has not yet been marketed in SL. Researchers have reported that \textit{B. caeruleus} is responsible for 10–15% of the snakebite in SL. ICP PAV does not contain \textit{B. caeruleus} venom in the immunization mixture, therefore this PAV is devoid of antibodies against this medically important snake venom. However, the paraspacific cross-neutralization of \textit{B. caeruleus} venom by antibodies against Elapidae family of snake venom in ICP PAV may not be ruled out; nevertheless, it cannot ensure full protection to SL krait bite patients. Consequently, it may be anticipated that owing to containing antibodies against \textit{B. caeruleus} venom, SL PAV will provide better protection against krait envenomation. In contrast, ICP PAV has a greater lethality neutralization potency against Viperidae venoms (DRV, ECV, and HHV) and a lower neutralization efficiency against NNV, compared to PSVPL SL PAV.

For the treatment against snakebite to be effective and convenient to the clinicians, the neutralization potency of PAV should preferably be adjusted according to the venom yield of snakes. It is further to be mentioned that the neutralization potency of the newly developed SL-specific PAV was based on the average venom yield of prevalent snake species with an intention to assist clinicians of SL who are well versed with the use and dose-regimen of Indian PAV. Hospital management of snakebite with similar dosage of SL-specific PAV compared to Indian PAV (which has been used for snakebite treatment by clinicians in SL for decades and they are well versed with the dosages) would be expected to be easier and more clinically relevant than the currently used Indian PAV. The published report on average venom yields of Sri Lankan species of snakes is not available, however, the same species of snakes in India have reported average venom yields of 330 mg, 22.7 mg, 200 mg and 6.25 mg for NNV, BCV, DRV and ECV, respectively. In another study, the average venom yields have been reported as 126.32 ± 4.31 mg, 8.352 ± 0.64 mg and 75.98 ± 3.66 mg for NNV, BCV and DRV, respectively. Thus, these two reports indicate a wide variation in the average venom yield for the same species of snakes in India probably due to difference in regions of study and/or age and size of the snakes. Further, the amount of venom that can be injected by envenomation into a patient would be expected to be proportional to the venom content (yield) of the species of snake. Therefore, the neutralization potency of PAV against DRV, HHV, and NNV should be higher than that against ECV and BCV, because the venom yield per bite of these two snakes should therefore be lower than the former three species of snakes. However, after the product (SL PAV) registration in SL further clinical trials may be undertaken for the effective clinical dose adjustment, if necessary.

Envenomation by the Elapidae family of snakes, such as the mambas (\textit{Dendroaspis sp.}), cobras (\textit{Naja sp.}), and kraits (\textit{Bungarus sp.}) induces a neurotoxic effect that is the primary cause of lethality; albeit, elapids also contain cytotoxins in their venom which lead to significant tissue necrosis. In this case, the neutralization of lethality would be an ideal model for assessing the pre-clinical efficacy of antivenoms. Nevertheless, the Viperidae snakes show a wide range of pathophysiological effects such as myonecrosis, dermonecrosis, hemorrhage, edema, coagulopathies, bleeding in various organs, hemodynamic disturbances, and renal disturbances. These effects are cumulatively responsible for the venom-induced lethality. Therefore, in the case of Viperidae...
venoms, pre-clinical evaluation of antivenoms by assessing the neutralization of lethality is not sufficient for an integrated evaluation of the antivenoms66. The WHO has recommended assessing the neutralization of other toxic activities with supplementary tests and the essential test of neutralization of lethality prior to marketing new antivenoms or introducing existing antivenoms into new geographical locales14.

The in vivo neutralization of venom-induced toxicity by the newly developed SL PAV has been determined in mice. Moreover, the toxicities of SL snake venoms are summarized in Supplementary Table S2. The tested pharmacological activities (i.e., hemorrhagic, necrotizing, pro-coagulant, defibrinogenating, and myotoxicity) of DRV, ECV, and HHV are well neutralized by SL PAV with variable potencies (Table 3, Supplementary Fig. S13). The neutralizing potency of SL PAV towards hemorrhagic activity, necrotizing activity, and defibrinogenating activity was found to be higher against DRV, in comparison to ECV and HHV. In contrast, the pro-coagulant activity displayed by HHV venom was better neutralized by SL PAV, compared to neutralization of the same activity against DRV and ECV (Table 3). This may be due to the HHV showing much less pro-coagulant activity compared to the other two Viperidae snake venoms (Supplementary Table S2).

In summary, grave concerns have been expressed by clinicians about using Indian PAVs for the treatment of snakebite in SL as it often shows only partial effectiveness in neutralizing the venom toxicity and it produces adverse clinical reactions in patients. Consequently, because of the long-standing demand for a country-specific PAV for treating snakebite, the PAV was developed against the venoms of five most medically important snakes of SL. The purity of the preparation and the safety of the newly developed SL PAV has been determined in mice. Moreover, the toxicities of SL snake venoms are summarized in Supplementary Table S2. The tested pharmacological activities (i.e., hemorrhagic, necrotizing, pro-coagulant, defibrinogenating, and myotoxicity) of DRV, ECV, and HHV are well neutralized by SL PAV with variable potencies (Table 3, Supplementary Fig. S13). The neutralizing potency of SL PAV towards hemorrhagic activity, necrotizing activity, and defibrinogenating activity was found to be higher against DRV, in comparison to ECV and HHV. In contrast, the pro-coagulant activity displayed by HHV venom was better neutralized by SL PAV, compared to neutralization of the same activity against DRV and ECV (Table 3). This may be due to the HHV showing much less pro-coagulant activity compared to the other two Viperidae snake venoms (Supplementary Table S2).

In summary, grave concerns have been expressed by clinicians about using Indian PAVs for the treatment of snakebite in SL as it often shows only partial effectiveness in neutralizing the venom toxicity and it produces adverse clinical reactions in patients. Consequently, because of the long-standing demand for a country-specific PAV for treating snakebite, the PAV was developed against the venoms of five most medically important snakes of SL. The purity of the preparation and the safety of the newly developed SL PAV was found to be satisfactory and no significant variation was seen in the PAV composition or potency between two batches (B1 and B2) of SL PAV; however, for an affirmative conclusion regarding batch-to-batch variation, future studies with more number of PAV batches are warranted. However, following the good manufacturing practice (GMP) by the antivenoms manufacturers can result in production of different batches of PAV with uniform potency and composition15. Further, the immunological cross-reactivity studies and enzyme neutralization assay documented the superiority of SL PAV in comparison to Indian PAVs against SL venoms. The pre-clinical study also provided convincing evidence for the neutralization of lethality and toxicity of SL snake venoms by SL PAV. Therefore, the findings of this study illustrate that the improved neutralization potency of PAV against SL snake venoms will greatly augment the hospital management of snake envenomation in SL. Further pre-clinical and clinical studies are still warranted to understand the complex pharmacokinetics and pharmacodynamics, and the venom-antivenom interactions in vivo that can neutralize the venom-induced toxicity.

**Materials and methods**

**Venoms and PAV.** The following five snake venoms (pooled from 5 to 6 snakes) from SL origin were used in this study: (i) *Naja naja* (NNV), (ii) *Daboia russelii* (DRV), (iii) *Bungarus caeruleus* (BCV), (iv) *Echis carinatus* (ECV), and (v) *Hypnale hypnale* (HHV). The venoms were collected from snakes of either sex of different age from various locations around Kandy city in SL as per prevalence of snakes in that area. The Saw scaled vipers (ECV) were collected from North SL (Jaffna). The collected venoms were stored lyophilized, and sent by University of Peradeniya (SL) who are collaborating with Premium Serums and Vaccines Pvt. Ltd. The equine

| Pharmacological properties | Neutralization of pharmacological properties [neutralization of toxicity of SL venom (mg)/mL of PAV] (n=5) |
|-----------------------------|---------------------------------------------------------------------------------------------------|
|                            | *Naja naja* | *Bungarus caeruleus* | *Daboia russelii* | *Echis carinatus* | *Hypnale hypnale* |
| MHD<sub>50</sub>            | NA          | NA                   | 24.7 ± 0.7        | 1.2 ± 0.1         | 1.1 ± 0.1         |
| MND<sub>50</sub>            | NA          | NA                   | 46.6 ± 0.3        | 0.7 ± 0.07        | 2.8 ± 0.1         |
| MCD-P<sub>100</sub>         | NA          | NA                   | NA               | 3.8 ± 0.5         | 70.0 ± 11.8       |
| MCD-F<sub>100</sub>         | NA          | NA                   | NA               | 4.1 ± 0.9         | 36.8 ± 7.4        |
| MDD<sub>50</sub>            | 2.3 ± 0.5   | 2.1 ± 0.4            | 2.2 ± 0.5         | 1.4 ± 0.3         | 3.7 ± 0.7         |

Table 3. Neutralization of in vivo pharmacological activities of SL snake venoms by newly developed SL PAV. Values are means ± SD of five values. aSignificance of difference of neutralization potency between *D. russelii*, *E. carinatus* and *H. hypnale* (p < 0.05). The PAV was dissolved in 10 mL of sterilized water. Neutralization of pharmacological activity is expressed as activity of venom (mg) neutralized per mL of reconstituted PAV in water. NA indicates no activity by the venom. bMinimum hemorrhagic dose (MHD) is defined as the amount of venom (in μg dry weight) which, when injected intradermally, induces in mice a 10 mm hemorrhagic lesion after a predefined time interval, usually 2–3 h, post injection. cMinimum necrotizing dose (MND) is defined as the smallest amount of venom (in μg dry weight) which, when injected intradermally into anaesthetized mice, results in a necrotic lesion of 5 mm diameter post 3 days of treatment. dThe minimum coagulant dose on plasma (MCD-P) is defined as the smallest amount of venom (in mg dry weight per liter of test solution or μg/mL) that induces clotting of citrated human plasma under the experimental conditions. eThe minimum coagulant dose on fibrinogen (MCD-F) is defined as the smallest amount of venom (in mg dry weight per liter of test solution or μg/mL) that clots a solution of bovine fibrinogen in 60 s at 37 °C. fMinimum defibrinogenating dose (MDD) is defined as the minimum dose of venom that produces incoagulable blood in all mice within 1 h of intravenous injection. gMinimum myotoxic dose (MDD) is characterized by the appearance of myoglobin in urine and by increments in the serum levels of muscle-derived enzymes, creatine kinase (CK).
PAV developed against SL snakes was obtained from Premium Serums and Vaccines Pvt. Ltd. (PSVPL), India [Batch-1 (B1): Batch no.—ASVS-SL/LY-001; manufacturing date: April 2019; expiry date: March 2023, Batch-2 (B2): Batch no.—ASVS-SL/LY-002; manufacturing date: April 2019; expiry date: March 2023]. The PAVs produced against the ‘big four’ venemous snakes of India were obtained from Bharat Serums and Vaccines Ltd. (BSVL). India (Batch no. A05319007, expiry date: October 2022). All of the PAVs used in this study contained pepsin digested and caprylic acid purified IgG [F(ab′)2]. Affinity-purified horse F(ab′)2, and horse IgG were purchased from Jackson Immuno Research Inc, USA and BioRad, USA, respectively. Anti-goat erythrocyte polyclonal antibody (raised in rabbit) was obtained from Fitzgerald Industries International, USA. The Pierce LAL Chromogenic Endotoxin Quantitation Kit was from Thermo Scientific, USA. The NHS-activated Sepharose 4 Fast Flow matrix was purchased from GE Healthcare. All other chemicals were of analytical grade and obtained from Sigma-Aldrich, USA. Human embryonic kidney 293 cells (HEK-293T), murine hepatoma Hepa 1–6 cell line (Hepa1-6), and differentiated rat skeletal (L6) myoblast cell lines were procured from ATCC (American type culture collection), USA.

Characterization of physicochemical properties of SL PAV. The texture, colour, and homogeneity of the PAV preparation were determined by visual inspection. The examination of textures like macroscopic collapse, color uniformity, cake shrinkage formation and adhesion properties of powder to the vials of PAVs was done by visual inspection and photographs of vials were also captured. PAVs were dissolved in 10 mL of sterilized de-ionized water (provided along with the antivenom) and the turbidity of the solution was assessed by a turbidimeter (model-CL52-D, Nephelometer, ELICO Ltd., India). The 2 mL PAV solutions were transferred to pre-weighed microfuge tubes and after centrifugation of the tubes at 10,000 rpm for 10 min, the solutions were decanted, and the tubes were dried in vacuum and weighed again to determine the presence of the insoluble component, if any. The pH of the aqueous PAV solution was determined using a digital pH meter (Eutech Instruments, pH 510, USA). For determining the residual moisture content, a measured amount of PAV was heated at 105 °C for 3 h in an oven and moisture content was determined by heat drying method.

Determination of purity of active substance in SL PAV. FPLC gel filtration chromatography method followed by SDS-PAGE analysis. The protein content of PAV was determined as described by Lowry et al. and the total protein concentration (in g/L) post dissolving the PAV content in 10 mL of water was determined. The homogeneity of the preparation was determined by size exclusion chromatography of a 50 mg/mL solution of PAV dissolved in 20 mM Tris–HCl containing 150 mM NaCl, pH 7.4 (equilibration buffer) at 4 °C as described previously. The size exclusion protein peaks and the crude PAV along with horse IgG and its pepsin digested product F(ab′), were separated by 12.5% SDS-PAGE under reduced and non-reduced conditions. Protein bands were visualized by Coomassie Brilliant Blue R-250 staining. After scanning the gel, intensities of the protein bands were determined by ImageQuant TL 8.1 software (GE Healthcare, Sweden). Considering that the molecular mass of F(ab′)2 is 100 kDa, the F(ab′)2 aggregate content of the PAVs was also analyzed by densitometry analyses of the SDS-PAGE protein bands of a mass greater than 100 kDa. The percent of aggregate content (band intensities above 100 kDa) in a particular batch of SL PAV was determined from the cumulative band intensity for that particular batch of PAV.

Tandem mass spectrometry analysis to determine the purity of active substance and presence of other contaminating proteins in SL PAV. The procedures described in this section is adopted from our previous publications. Hundred microgram proteins of PAV batches were subjected to reduction (10 mM DTT), alkylation (55 mM iodoacetamide) and then digested with trypsin at an enzyme: substrate ratio of 1:30 for overnight (~ 16 h) at 37 °C. The trypsin-digested peptides were desalted and concentrated using ZipTip C18 tips following the manufacturer’s protocol. The tryptic fragments of PAV were reconstituted in 0.1% formic acid and separated on a Zorbax 300SB-C18 analytical column (75 μm × 150 mm, 3.5 μm, Agilent), coupled to an Agilent 1200 HPLC, at a flow rate of 300 nL/min. The mobile phase gradient for separation of the peptides was set as: 11% B for 5 min, 11 to 25% B for 20 min, 25 to 53% B for 16 min, 53 to 100% B for 5 min, 100% B for 4 min, and then 11% B for 4 min. Solvent A and B were 0.1% formic acid and 80% acetonitrile (ACN) containing 0.1% formic acid, respectively.

The peptides eluted from the HPLC column were then fed into a Nanomate Triversa (Advion BioSciences, Ithaca, NY), equipped with an LC coupler and electrospray ionization (ESI) nanospray chip. The LC coupler connects the flow from the HPLC to the ESI chip, where the nano-ESI generated ions were transferred into an LTQ Orbitrap Discovery hybrid mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). The ionization voltage was set to 1.7 kV and the raw data were acquired in a data-dependent acquisition (DDA) mode by Xcalibur software (Thermo Fisher Scientific, Bremen, Germany). One MS survey scan was followed by 5 MS/MS scans with exclusion duration of 120.0 s during DDA. Survey full-scan MS spectra (from m/z 300–2000 with lock mass set to 445.12 corresponding to polysiloxane) were acquired in Fourier Transform (FT) mode with a resolution of 30,000 (full width at half-maximum). Subsequent fragmentation (MS/MS) was collision-induced dissociation (CID) with normalized collision energy set to 35% in linear ion trap mode. The MS/MS triggering conditions were minimum signal intensity of 10,000; charge state of +2, +3; maximum injection time for MS/MS was 500 ms; and isolation width was 2 amu.

The raw LC–MS/MS data were processed to generate peak list in Mascot generic format (*mgf) using ProteoWizard release version 3.0.331. The peak lists were then searched against the Equus caballus (taxid 9796) protein entries of the UniProt database (version 2019_07) using the Mascot search engine (Matrix Science, London, UK, version: 2.4). The following search parameters were used; enzyme: trypsin, maximum missed cleavage sites: 2,
Characterization of in vitro safety profile of SL PAV.  Determination of Fc content in the IgG molecule and assessment of complement activation.  The incomplete pepsin digestion of IgG (Fc content of IgG) in the PAV preparation, if any, was determined by ELISA and Western blot analysis using HRP (horseradish peroxidase)-conjugated rabbit anti-horse IgG Fc specific antibody (Sigma Aldrich, USA)\(^\text{38}\). For the ELISA, 100 ng of PAV protein (in triplicate) or BSA (bovine serum albumin) (negative control) or PBS (reagent control) was coated in the 96 wells of the microtiter plate for overnight incubation (~18 h) at 4 °C. After blocking the wells with 5% fat-free skimmed milk, 100 µL of anti-horse IgG Fc specific antibody (1:2000 dilution) or PBS (control) was added and the color was developed by adding TMB (3,3',5,5'-tetramethylbenzidine)/H\(_2\)O\(_2\) as the substrate\(^\text{44}\). Absorbance was measured at 492 nm in a microplate reader (Multiskan GO, Thermo Scientific, USA). A standard curve of the graded concentrations of purified horse IgG was prepared and Fc content was determined by ELISA under identical experimental conditions. The Fc content of test samples was compared to the standard curve of horse IgG.

For the immunoblot analysis, 20 µg of PAV protein (in triplicate) and horse IgG after separation by 12.5% SDS-PAGE (reduced) was transferred to a PVDF membrane in a semi-dry blotter (Amersham Bioscience, Sweden). After blocking the protein unbound portion of the membrane (non-specific binding sites) by 5% fat-free skimmed milk, it was thoroughly washed with PBS-T in an incubator shaker and the membrane was incubated with HRP-conjugated anti-horse rabbit IgG Fc specific antibody (1:2000 dilution) for 1 h at room temperature. After washing, the membrane blot was developed using the TMB/H\(_2\)O\(_2\) substrate\(^\text{44}\). The image was photographed, scanned (Epson image scanner, Epson America, Inc.) and the densitometry analysis was done by ImageQuant TL 8.1 software (GE Healthcare, Sweden). The percent content of Fc in the purified horse IgG was considered as 100% and the other values were compared to that\(^\text{39}\).

Classical and alternative pathways of complement activation were determined by percentage of hemolysis induced by SL PAV (batch 1 and batch 2) samples\(^\text{37}\). Human blood samples from healthy donor were collected without anticoagulant and allowed to clot at room temperature for 4 h. The collection of blood from healthy volunteers (who were not under medication) was approved by the Tezpur University Ethical Committee and assessment of complement activation.

For determination of complement activation by classical pathway (CP) goat erythrocytes were washed with 1× PBS, pH 7.4 for three times, re-suspended in the same buffer and then incubation with anti-goat erythrocyte antibodies (1:500 dilutions) at 37 °C for 15 min. The antibody-sensitized goat erythrocytes were washed with 1× PBS pH 7.4 buffer and 2% (v/v) erythrocytes suspension was prepared in veronal buffered saline (VBS\(^\text{42}\)—10 mM Na-barbitone, 0.15 mM CaCl\(_2\) and 0.5 mM MgCl\(_2\), pH 7.4).

For alternative pathway (AP) of complement activation, goat erythrocytes were washed with 1× PBS, pH 7.4 and re-suspended in AP buffer (10 mM Na-barbitone, 10 mM EGTA and 0.5 mM MgCl\(_2\); pH 7.4) at a final concentration of 2% (v/v). Fifty micro liters of antibody sensitized goat erythrocytes (for classical pathway) or goat erythrocytes (for alternative pathway) were added to wells of a 96-well microtiter plate containing 50 µL of human serum pre-incubated with 50 µL of SL PAV (1 mg) at 37 °C. The mixture (final volume 150 µL) was incubated for 30 min at 37 °C and then 150 µL of VBS\(^\text{43}\) was added to each well. The plate was centrifuged at 4300 rpm for 10 min at 4 °C to pellet down the erythrocytes\(^\text{43}\).

For determination of complement activation by classical pathway (CP) goat erythrocytes were washed with 1× PBS, pH 7.4 for three times, re-suspended in the same buffer and then incubation with anti-goat erythrocyte antibodies (1:500 dilutions) at 37 °C for 15 min. The antibody-sensitized goat erythrocytes were washed with 1× PBS pH 7.4 buffer and 2% (v/v) erythrocytes suspension was prepared in veronal buffered saline (VBS\(^\text{42}\)—10 mM Na-barbitone, 0.15 mM CaCl\(_2\) and 0.5 mM MgCl\(_2\), pH 7.4).

For alternative pathway (AP) of complement activation, goat erythrocytes were washed with 1× PBS, pH 7.4 and re-suspended in AP buffer (10 mM Na-barbitone, 10 mM EGTA and 0.5 mM MgCl\(_2\); pH 7.4) at a final concentration of 2% (v/v). Fifty micro liters of antibody sensitized goat erythrocytes (for classical pathway) or goat erythrocytes (for alternative pathway) were added to wells of a 96-well microtiter plate containing 50 µL of human serum pre-incubated with 50 µL of SL PAV (1 mg) at 37 °C. The mixture (final volume 150 µL) was incubated for 30 min at 37 °C and then 150 µL of VBS\(^\text{43}\) was added to each well. The plate was centrifuged at 1300 rpm at 4 °C for 5 min (Heraeus multifuge X1R, Thermo Scientific, USA) and 50 µL of supernatant from each well was transferred to a new 96-well plate containing 200 µL of water. The contents were mixed well by shaking, and the absorbance of mixture was measured at 414 nm in a microplate reader. The results were expressed as the percentage of CH50/mL (classical pathway) or AP50/mL (alternative pathway) activation compared with NHS incubated with saline (100%).

Determination of IgA and IgE contamination.  The occurrence of IgA and IgE in the SL PAVs, if any, was determined by Western blot analysis and ELISA of PAV against HRP-conjugated anti-horse IgA and anti-horse IgE antibodies, respectively (1:2000 dilution) as described previously\(^\text{37}\). As a negative control, 20 µg (for the Western blot analysis) or 100 ng (for the ELISA) of BSA was used. The blots were scanned (EPSON image scanner, Epson America, Inc.) and their densitometry analysis was done by ImageQuant TL 8.1 software (GE Healthcare, Sweden).

Sterility test and determination of endotoxin level.  The sterility of the SL PAV was tested according to the WHO guidelines\(^\text{44}\). One mg of PAV solution in sterile water was incubated in trypticase soy broth and thioglycolate medium. Control culture flasks were included for each medium. Flasks were incubated at 25 °C or at 35 °C for...
14 days in trypticase soy broth and thioglycolate medium to test for fungal and bacterial cultures, respectively, using the appropriate controls. Culture flasks were examined daily for bacterial or fungal growth by checking the optical density in a spectrophotometer at 600 nm.

The level of endotoxin contamination in SL PAV, if any, was determined using a commercial diagnostic kit (Pierce LAL Chromogenic Endotoxin Quantitation Kit, Thermo Scientific, USA). Briefly, a standard curve of graded concentrations of *E. coli* endotoxin was plotted so that the endotoxin concentration in test sample can be determined as low as 0.1 EU/mL. For endotoxin determination, 50 µL of SL PAV samples in triplicate was added to wells of microtiter plate and the plates were incubated at 37 °C for 5 min at dark. Then, 50 µL of Limulus amebocyte lysate (LAL) to each well was added, mixed gently on a plate shaker for 10 s followed by incubation at 37 °C for 10 min. Thereafter 100 µL of chromogenic substrate solution was added to each well and incubated for 6 min at 37 °C. The reaction was stopped by adding 50 µL of 25% acetic acid and the absorbance of mixture was read at 405 nm in a microplate reader (Multiskan GO, Thermo Scientific, USA). From the standard curve, the concentration of endotoxin in PAV samples was determined. As a negative control, BSA was used.

**Determination of preservative content.** The use of a specified amount of preservative (*m*-cresol) in PAV preparations for their long-term storage was approved by the WHO in 2016. The m-cresol content was determined by reversed-phase ultra-high performance liquid chromatography (RP-UHPLC) of SL PAV on an Acclaim 300 C18 RP-UHPLC column (2.1 × 150 mm, 3 µm) pre-equilibrated with 60% methanol in 0.1% (v/v) trifluoroacetic acid (TFA) as described previously. The flow rate was 0.5 mL/min and the column temperature was maintained at 30 °C. The isocratic programme for the mobile phase was optimized for 18 min. The detection of *m*-cresol was observed at 254 nm. The percentage of *m*-cresol was determined against a standard curve of *m*-cresol run in UHPLC under identical experimental conditions.

**Assessment of in vitro hemolytic activity, and cytotoxicity against mammalian cells.** The in vitro direct and indirect hemolytic activity of SL PAV (20 µg/mL) was determined against washed human erythrocytes. The in vitro cell cytolysis was determined by incubating 10 µg/mL of PAV or PBS (control) against human embryonic kidney 293 (HEK-293T), murine hepatoma Hepa 1–6 (Hepa1-6), and differentiated rat skeletal (L6) myoblast cells (1 × 10^5 cells/mL) grown in DMEM for 72 h at 37 °C and 5% CO_2. Thereafter, cell viability was determined by the MTT-based method and the result was expressed as PAV-induced cell death (in percentage), if any, with respect to control (PBS-treated cells). H_2O_2 was used as a cytotoxic agent (positive control).

**Comparison of SL PAV with Indian PAV in terms of immunological cross-reactivity, and in vitro neutralization of some enzyme activities and pharmacological properties of SL snake venoms.** The immunological cross-reactivity of snake venoms against SL PAV and Indian PAV raised against venoms of the Big Four snakes of India was determined by ELISA and Western blot analysis. Briefly, for ELISA 100 ng of venom was coated for overnight at 4 °C in microtiter ELISA plate. After washing the wells by using washing buffer (phosphate buffer saline containing 0.5% tween-20) the wells were blocked by 5% skimmed milk. The SL PAV or Indian PAV (1 mg/mL) were used as primary antibody (1:500 dilutions) and incubated for 2 h with venom or BSA (blank control) at room temperature. For negative control, the venom samples were treated with naïve horse IgG and developed in parallel. After incubation with primary antibody, the excess antibodies were washed using washing buffer and incubated with anti-horse IgG HRP-conjugated secondary antibody (produced in rabbit) for 2 h at room temperature (1:2000 dilutions). The wells are washed properly and TMB/H_2O_2 substrate was used for development of color. The reaction was stopped immediately by 2 M H_2SO_4 and the absorbance was read at 492 nm. For presenting the data, the absorbance values of PAV against venom samples was deducted from the absorbance of negative control.

Immunoblotting experiments were performed as described previously by resolving the venom proteins in 12.5% SDS-PAGE under reduced conditions. The SDS-PAGE protein bands were transferred to PVDF membrane in a semi-dry gel transfer system (Amersham Bioscience, UK) at 1.2 mA/cm^2 of membrane area for 2 h. The transfer efficiency was checked by Ponceau S staining of the membranes. The membranes were blocked by 5% skimmed milk (prepared in Tris buffered saline with 0.1% Tween-20; TBS-T) for overnight at 4 °C. Thereafter, the membranes were washed with TBS-T and incubated with primary antibody (15 mg/mL PAVs) at 1:1000 dilutions for 1 h at room temperature. The excess unbound antibodies were washed with TBS-T and incubated with anti-horse IgG ALP-conjugated secondary rabbit anti-horse antibodies for 1 h at room temperature. Thereafter, the blots were developed using 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium (BCIP/NBT) kit (Sigma-Aldrich, USA) and scanned (Epson Expression 11000XL, USA). Venom samples treated with horse naïve IgG served as negative control. Densitometry analysis of the blots was done using ImageQuant TL software 8.1 (GE Healthcare, Sweden).

Neutralization of some enzyme activities (ATPase, ADPase, AMPase, l-amino acid oxidase, fibrino(gen) lytic, metalloproteinase, hyaluronidase, phospholipase A_2) and pharmacological properties (pro/anti-coagulant activity) of SL snake venoms by the newly developed SL PAV and Indian PAVs was determined as described previously. Briefly, venom (10 µg) was pre-incubated with PAV (100 µg) in a predetermined ratio (1:10, protein: protein) for 30 min at 37 °C followed by assaying the mixture for enzymatic activities and in vitro pharmacological properties of venom. The enzymatic activities and pharmacological properties displayed by crude venom were considered as 100% activity and other values were compared to that.

**Assessment of pre-clinical efficacy: neutralization of lethality and in vivo pharmacological properties of snake venoms by SL PAV.** Ethical statement. In vivo neutralization of lethality and other pharmacological effects of snake venom hemorrhagic activity, necrotizing activity, pro-coagulant activity, defi-
brachtogenating activity, and myotoxicity of SL snake venoms by PAV raised against these snakes were evaluated in laboratory inbred Swiss albino mice (males and females) weighing between 18 and 20 g, age 3 to 4 weeks, following the WHO guidelines. Animal experiments were conducted in the animal house facility of Premium Serums & Vaccines Pvt. Ltd., Pune. All animal experiments were done in accordance with the ARRIVE (Animal Research: Reporting of in Vivo Experiments) guidelines and ethical guidelines of the “Committee for the purpose of control and supervision of experiments in animals (CPCSEA)” (the approval numbers for the animal experiments are shown in Supplementary Table S3). Mice were kept in cages in a standard environment with temperature between 22 and 25 °C, relative humidity between 50 and 60%, 12 h daylight cycle and 12–15 air changes per hour. Dry food pellets (Nutritive Life Sciences, Pune) and purified filtered water were provided ad libitum.

**Determination of in vivo neutralization of lethality.** The stock solution of venom (1 mg/mL) was diluted in normal saline to prepare different concentrations of venom solution (0.8-fold decrement) so that the middle dose was expected to be the LD50 dose of the venom (where 50% of the test animals died). To determine the LD50, graded concentrations of venom from each species of snake (in 5 mL of normal saline) were injected intravenously into a group of five mice. Animals were observed for 48 h and deaths during this period, if any, were recorded. The LD50 was calculated by the Reed and Muench method (1938) by using the following formula:

\[
\text{Log of LD50} = \frac{[\text{Mortality above 50%}] - [\text{Mortality below 50%}]}{[\text{Mortality above 50%}] - [\text{Mortality below 50%}]} \times \text{Log of decrement}
\]

A fixed amount of venom (“challenge dose”, usually corresponding to 5LD50) was mixed with graded concentrations (1.5 fold) of the PAV and adjusted to a constant final volume with saline. The mixtures were incubated for 30 min at 37 °C, and then aliquots of a precise volume (maximum 0.5 mL intravenously) of each mixture were injected into groups of 6 Swiss albino mice. A control group was injected with a mixture of the venom “challenge dose” with saline solution alone (no PAV) to confirm that the venom “challenge dose” induces 50% lethality. After injection, deaths were recorded at 48 h (intravenous test) and the results were analyzed using using Reed and Muench method. One antivenom ED50 dose is the amount of antivenom, or the venom/PAV ratio, resulting in the survival of 50% of mice injected with a mixture of PAV and a lethal quantity of venom. The ED50 results were expressed as mg of venom neutralized by per mL of PAV and value was calculated using following formula:

\[
\text{Log of ED50} = \frac{[\text{Mortality above 50%}] - [\text{Mortality below 50%}]}{[\text{Mortality above 50%}] - [\text{Mortality below 50%}]} \times \text{Log of dilution factor}
\]

In addition to the neutralization potency (mg of venom neutralized by 1 mL of PAV) value, a universal unit for comparison of ED50 values in terms of µL PAV required/ mg venom were also calculated.

**Neutralization of in vivo pharmacological activities of snake venoms.** To determine the hemorrhagic activity, five different concentrations of venom solutions (50 µL) or normal saline (control) were injected intradermally in the shaved skin of lightly anesthetized mice (n = 5). After 3 h post injection, mice were euthanized using a carbon dioxide asphyxiation method. The area of the injected skin was measured using calipers in two directions. The mean diameter of the hemorrhagic lesion for each venom dose was calculated and the mean lesion diameter was plotted against each venom dose to determine the minimum hemorrhagic dose (MHD). One unit of MHD is defined as the dose of venom that produces 10 mm diameter of skin hemorrhage.

To determine the venom necrotizing activity, the above procedure was followed and the size of the dermonecrotic lesion was measured. The mean diameter of the dermonecrotic lesion for each venom dose was calculated and mean lesion diameter was plotted against venom dose to determine the minimum necrotic dose (MND), which is defined as the venom dose that produces skin necrosis with a diameter of 5 mm.

To determine the in vivo defibrinogenating activity, graded concentrations of venom in 0.2 mL of normal saline or only normal saline (control) were intravenously (i.v.) injected in a group of five mice. After 1 h following the injection, blood was withdrawn by cardiac puncture from the anesthetized mice and transferred to glass tubes. Clot formation was observed visually by the tilting of the tubes. The minimum defibrinogenating dose (MDD) is defined as the amount of injected venom that does not show in vitro blood clot formation.

To determine myotoxic activity, five different doses of venom dissolved in 50 µL of normal saline were injected into the right gastrocnemius muscle in each mouse (n = 5). Control animals received an injection of the same volume of normal saline. Blood was withdrawn from the tail tip of the anesthetized mice 3 h post injection and serum creatine phosphokinase (CPK) activity was determined using a commercial diagnostic kit (Tulip Diagnostic, India). Statistical analysis. The significance of difference for more than one set of data was analyzed by one way ANOVA. The significance of difference between two sets of data was determined by Student’s t test, using Sigma Plot 11.0 for Windows (version 10.0). A p value of ≤ 0.05 between two sets of data was considered to be statistically significant.

**Ethics declaration.** Authors confirm that all methods were carried out in accordance with relevant guidelines and regulations and informed consent was obtained from all subjects. All the animal experimental protocols...
were approved by Premium Serum and Vaccines Pvt. Ltd., Pune, India, following the ARRIVE guidelines and guidelines of Committee for the purpose of control and supervision of experiments in animals (CPCSEA). The details regarding ethics committee/PSVPL animal ethical review board approval numbers for animal experiments are mentioned in Supplementary Table S3.

Data availability
Authors confirm that all relevant data are included in the paper and/or its supplementary information file.

Received: 15 November 2020; Accepted: 6 July 2021

References
1. Kasturiratne, A. et al. The global burden of snakebite: A literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 5, e218 (2008).
2. Ediriweera, D. S. et al. Mapping the risk of snakebite in Sri Lanka-a national survey with geospatial analysis. PLoS Negl. Trop. Dis. 10, e0004813 (2016).
3. Keyler, D. et al. Antivenom for snakebite envenoming in Sri Lanka: The need for geographically specific antivenom and improved efficacy. Toxicon 69, 90–97 (2013).
4. Kasturiratne, A. et al. Estimates of disease burden due to land-snake bite in Sri Lankan hospitals. Southeast Asian J. Trop. Med. Public Health 36, 733 (2005).
5. De Silva, H., Gunatilake, S., Kularatne, S. & Sellahewa, K. Anti-venom for snakebite in Sri Lanka. Ceylon Med. J. 47, 43–45 (2011).
6. Patra, A. & Mukherjee, A. K. Proteomic analysis of Sri Lanka Echis carinatus venom: Immunological cross-reactivity and enzyme neutralization potency of Indian polyantivenom. J. Proteome Res. 19, 3022–3032 (2020).
7. Sintiprungrat, K. et al. A comparative study of venomics of Naja naja from India and Sri Lanka, clinical manifestations and antivenomics of an Indian polyspecific antivenom. J. Proteomics 132, 131–143 (2016).
8. Oh, A. M. F., Tan, C. H., Ariaraneey, G. C., Quraishi, N. & Tan, N. H. Venomics of Bungarus caeruleus (Indian krait)-Comparative venom profiles, variable immunoreactivities among specimens from Sri Lanka, India and Pakistan. J. Proteomics 164, 1–18 (2017).
9. Tan, N. H. et al. Functional venomics of the Sri Lankan Russell’s viper (Daboia russelli) and its toxicological correlations. J. Proteomics 128, 403–423 (2015).
10. Tan, C. H. et al. Cross neutralization of Hypnale hypnale (hump-nosed pit viper) venom by polyclonal and monovalent Malayan pit viper antivenoms in vitro and in a rodent model. Acta Trop. 117, 119–124 (2011).
11. Ariaraneey, C. A. et al. An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell’s viper (Daboia russelli russelli). Trans. R Soc. Trop. Med. Hyg. 95, 74–80 (2001).
12. Lack of effective antivenom. Ariaraneey, C. et al. Frequent and potentially fatal envenoming by hump-nosed pit vipers (Hypnale hypnale and H. nepa) in Sri Lanka. Trans. R. Soc. Trop. Med. Hyg. 102, 1120–1126 (2008).
13. Villalta, M. et al. Development of a new polyspecific antivenom for snakebite envenoming in Sri Lanka: Analysis of its preclinical efficacy as compared to a currently available antivenom. Toxicon 122, 155–159 (2016).
14. WHO. WHO guidelines for the production, control and regulation of snake antivenom immunoglobulins. Geneva (2016).
15. Patra, A., Herrera, M., Gutiérrez, J. M. & Mukherjee, A. K. The application of laboratory-based analytical tools and techniques for the quality assessment and improvement of commercial antivenoms used in the treatment of snakebite envenomation. Drug Test. Anal. 13, 1467–1588 (2021).
16. Herrera, M. et al. Physicochemical characterization of commercial freeze-dried snake antivenoms. Toxicon 126, 32–37 (2017).
17. Wang, D., Hey, J. & Nail, S. Effect of collapse on the stability of freeze-dried recombinant factor VIII and α-amylase. J. Pharm. Sci. 93, 1253–1263 (2004).
18. Mohapatra, B. et al. Snakebite mortality in India: A nationally representative mortality survey. PLoS Negl. Trop. Dis. 5, e1018 (2011).
19. Patra, A., Kalita, B. & Mukherjee, A. K. Assessment of quality, safety, and pre-clinical toxicity of an equine polyspecific antivenom (Pan Africa): Determination of immunological cross-reactivity of antivenom against venom samples of Elapidae and Viperidae snakes of Africa. Toxicon 153, 120–127 (2018).
20. Laloo, D. G. & Theakston, R. D. Snake antivenoms. J. Toxicol. Clin. Toxicol. 41(277–290), 317–327 (2003).
21. Vargas, M. et al. Preclinical evaluation of caprylic acid-fractionated IgG antivenom for the treatment of Taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea. PLoS Negl. Trop. Dis. 5, e1144 (2011).
22. Gutiérrez, J. M., León, G. & Lomonte, B. Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clin. Pharmacokinet. 42, 721–741 (2003).
23. Mukherjee, A. K. Species-specific and geographical variation in venom composition of two major cobras in Indian subcontinent: Impact on polyclonal antivenom therapy. Toxicon 188, 150–158 (2020).
24. Calvete, J. J., Sanz, L., Angulo, Y., Lomonte, B. & Gutiérrez, J. M. Venoms, venomics, antivenomics. FEBS Lett. 583, 1736–1743 (2009).
25. Tan, K. Y., Tan, C. H., Fung, S. Y. & Tan, N. H. Venomics, lethality and neutralization of Naja kaouthia (monocled cobra) venom from three different geographical regions of Southeast Asia. J. Proteomics 120, 105–125 (2015).
26. Tan, C. H., Liew, J. L., Tan, K. Y. & Tan, N. H. Assessing SABU (Serum Anti Bisa Ular), the sole Indonesian antivenom: A proteomic analysis and neutralization efficacy study. Sci. Rep. 6, 37299 (2016).
27. Tan, C. H., Liew, J. L., Chong, H. P. & Tan, N. H. Protein decomposition and proteomics: A complementary assessment method of the physicochemical purity of antivenom. Biologicals 69, 22–29 (2021).
28. Patra, A., Banerjee, D., Dasgupta, S. & Mukherjee, A. K. The in vitro laboratory tests and mass spectrometry-assisted quality assessment of commercial polyvalent antivenom raised against the ‘Big Four’ venomous snakes of India. Toxicon 192, 15–31 (2021).
29. Rawerith, R. & Ratanabanangkoon, K. Fractionation of equine antivenom using caprylic acid precipitation in combination with cationic ion-exchange chromatography. J. Immunol. Methods. 282, 63–72 (2003).
30. Ramos-Cerrillo, B. et al. Characterization of a new polyvalent antivenom (Antivipmyn® Africa) against African vipers and elapid. Toxicon 52, 881–888 (2008).
31. Kurtovic, T. et al. Refinement strategy for antivenom preparation of high yield and quality. PLoS Negl. Trop. Dis. 13, e0007431 (2019).
32. León, G., Monge, M., Rojas, E., Lomonte, B. & Gutiérrez, J. M. Comparison between IgG and F (ab′) 2 polyclonal antivenoms: Neutralization of systemic effects induced by Bothrops asper venom in mice, extravasation to muscle tissue, and potential for induction of adverse reactions. Toxicon 39, 793–801 (2001).
33. Garcia, M. et al. Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation. Biologicals 30, 143–151 (2002).
34. Otero, R. et al. A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and PortIridium snake bites in Colombia: Correlation between safety and biochemical characteristics of antivenoms. *Toxicon* **37**, 895–908 (1999).

35. Otero-Patiño, R. et al. A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms for Bothrops snake bites in Uraba, Colombia. The Regional Group on Antivenom Therapy Research (REGATHER). *Am. J. Trop. Med. Hyg.* **58**, 183–189 (1998).

36. Eursakun, S., Simsiriwong, P. & Ratanabanangkoon, K. Studies on the fractionation of equine antivenom IgG by combinations of ammonium sulfate and caprylic acid. *Toxicon* **60**, 1022–1029 (2012).

37. Siqueir-Paristao, C. C., Marcelino, J. R., da Cunha, L. E. R., Gutiérrez, J. M. & Tambourgi, D. V. Anticomplementary activity of horse IgG and F(ab')2 antivenoms. *Am. J. Trop. Med. Hyg.* **90**, 574–584 (2014).

38. WHO. Guidelines for the clinical management of snake bites in the South-East Asia Region. (2005).

39. Davis, A. Guidelines for the clinical management of snake bites in the south-east Asia region, 1–67 (World Health Organization, Regional Office for South East Asia, 2005).

40. Cadieux, J., Kuzio, J., Milazzo, F. & Kropinski, A. Spontaneous release of lipopolysaccharide by Pseudomonas aeruginosa. *J. Bacteriol.* **155**, 817–825 (1983).

41. Solano, G., Gómez, A. & León, G. Assessing endotoxins in equine-derived snake antivenoms: Comparison of the USP pyrogen test and the Limulus Amoebocyte Lysate assay (LAL). *Toxicon* **105**, 13–18 (2015).

42. Maduwaq, K., Silva, A., O’Leary, M. A., Hodgson, W. C. & Ibister, G. K. Efficacy of Indian polyvalent snake antivenoms against Sri Lankan snake venoms: Lethality studies or clinically focussed in vitro studies. *Sci. Rep.* **6**, 26778 (2016).

43. Mukherjee, A. K., Kalita, B. & Mackessy, S. P. A proteomic analysis of Pakistan Daboia russelii russelii venom and assessment of potency of Indian polyvalent and monovalent antivenom. *J. Proteomics* **144**, 73–86 (2016).

44. Kalita, B., Patra, A. & Mukherjee, A. K. Unraveling the proteome composition and immuno-profiling of western India Russell’s viper venom for in-depth understanding of its pharmacological properties, clinical manifestations, and effective antivenom treatment. *J. Proteome Res.* **16**, 583–598 (2017).

45. Patra, A., Kalita, B., Chanda, A. & Mukherjee, A. K. Proteomics and antivenomics of Echis carinatus carinatus venom: Correlation with pharmacological properties and pathophysiology of envenomation. *Sci. Rep.* **7**, 17119 (2017).

46. Senji Laxne, B. R. et al. Beyond the “big four”: Venom profiling and understanding of the medically important yet neglected Indian snakes reveals disturbing antivenom deficiencies. *PloS Negl. Trop. Dis.* **13**, e0007899 (2019).

47. Faisal, T. et al. Proteomics, functional characterization and antivenom neutralization of the venom of Pakistani Russell’s viper (Daboia russelli) from the wild. *J. Proteomics* **183**, 1–13 (2018).

48. Kalita, B., Patra, A., Das, A. & Mukherjee, A. K. Proteomic analysis and immuno-profiling of eastern India Russell’s viper (Daboia russelli) venom: Correlation between RVV composition and clinical manifestations post RV bite. *J. Proteome Res.* **17**, 2819–2833 (2018).

49. Kalita, B., Singh, S., Patra, A. & Mukherjee, A. K. Quantitative proteomic analysis and antivenom study revealing that neurotoxic phospholipase A2 enzymes, the major toxin class of Russell’s viper venom from southern India, shows the least immuno-recognition and neutralization by commercial polyvalent antivenom. *Int. J. Biol. Macromol.* **118**, 375–385 (2018).

50. Patra, A., Chanda, A. & Mukherjee, A. K. Quantitative proteomic analysis of venom from Southern India common krait (Bungarus caeruleus) and identification of poorly immunogenic toxins by immunoelectrophoretic profiling against commercial antivenom. *Expert Rev. Proteomics* **16**, 457–469 (2019).

51. Chanda, A., Patra, A., Kalita, B. & Mukherjee, A. K. Proteomics analysis to compare the venom composition between Naja naja and Naja kaouthia from the same geographical location of eastern India: Correlation with pathophysiology of envenomation and immunological cross-reactivity towards commercial polyvalent venom. *Expert Rev. Proteomics* **15**, 949–961 (2018).

52. Chanda, A., Kalita, B., Patra, A., Senevirathne, W. D. S. T. & Mukherjee, A. K. Proteomic analysis and antivenomics study of Western India Naja naja venom: Correlation between venom composition and clinical manifestations of cobra bite in this region. *Expert Rev. Proteomics* **16**, 171–184 (2019).

53. Deka, A., Gogoi, A., Das, D., Purkayastha, J. & Doley, R. Proteomics of Naja kaouthia venom from North East India and assessment of Indian polyvalent antivenom by third generation antivenomics. *J. Proteomics* **207**, 103463 (2019).

54. Tan, C. H., Tan, N. H., Sim, S. M., Fung, S. Y. & Gnanathasan, C. A. Proteomic investigation of Sri Lankan hump-nosed pit viper (Hypnale hypnale) venom. *Toxicon* **93**, 164–170 (2015).

55. Chanda, A. & Mukherjee, A. K. Quantitative proteomics to reveal the composition of Southern India spectacled cobra (Naja naja) venom and its immunological cross-reactivity towards commercial antivenom. *Int. J. Biol. Macromol.* **160**, 224–232 (2020).

56. Kalita, B., Mackessy, S. P. & Mukherjee, A. K. Proteomic analysis reveals geographic variation in venom composition of Russell’s viper in the Indian subcontinent: Implications for clinical manifestations post-envenomation and antivenom treatment. *Expert Rev. Proteomics* **15**, 837–849 (2018).

57. Mukherjee, A., Ghasil, S. & Maity, C. Some biochemical properties of Russell’s viper (Daboia russelli) venom from Eastern India: Correlation with clinico-pathological manifestation in Russell’s viper bite. *Toxicon* **58**, 163–175 (2000).

58. Gnanathasan, A., Rodrigo, C., Peranatharajah, T. & Coonghe, A. Saw-scaled viper bites in Sri Lanka: Is it a different subspecies? Clinical evidence from an authenticated case series. *The Am. J. Trop. Med. Hyg.* **86**, 254–257 (2012).

59. Katkar, G. D. et al. NETox and lack of DNase activity are key factors in Echis carinatus venom-induced tissue destruction. *Nat. Commun.* **7**, 11361 (2016).

60. Mukherjee, A. K. & Mackessy, S. P. Biochemical and pharmacological properties of a new thrombin-like serine protease (Russelbin) from the venom of Russell’s viper (Daboia russelii russelii) and assessment of its therapeutic potential. *Biochim. Biophys. Acta* **1830**, 3476–3488 (2013).

61. Rucavado, A. et al. Characterization of asperrin, a platelet aggregating component from the venom of the snake Bothrops asper which induces thrombocytopenia and potentiates metalloproteinase-induced hemorrhage. *Thromb. Haemost.* **86**, 710–715 (2001).

62. Thakur, R., Chattopadhyay, P., Ghosh, S. S. & Mukherjee, A. K. Elucidation of procoagulant mechanism and pathophysiological significance of a new prothrombin activating metalloproteinase purified from Daboia russelli russelli venom. *Toxicon* **100**, 1–12 (2015).

63. Thakur, R. & Mukherjee, A. A Brief Appraisal on Russell’s Viper Venom (Daboia russelli russelli) Proteins (Springer, 2015).

64. Liu, C.-c. et al. Snake venom proteome of Protobothrops mucrosquamatus in Taiwan: Delaying venom-induced lethality in a rodent model by inhibition of phospholipase A2 activity with varespladib. *J. Proteomics* **234**, 104084 (2021).

65. Bhät, M. K. & Gowda, T. Isolation and characterization of a lethal phospholipase A2 (NN-1V-B-1PLA2) from the Indian cobra (Naja naja) venom. *Biochem. Int.* **25**, 1023–1034 (1991).

66. Gutiérrez, J. M. et al. Preclinical evaluation of the efficacy of antivenoms for snakebite envenomation: State-of-the-art and challenges ahead. *Toxins* **9**, 163 (2017).

67. Ariaratnam, C. A., Sheriff, M. H. R., Arambepola, C., Theakston, R. D. G. & Warrell, D. A. Syndromic approach to treatment of snake bite in Sri Lanka based on results of a prospective national hospital-based survey of patients envenomed by identified snakes. *Am. J. Trop. Med. Hyg.* **81**, 725–731 (2009).

68. Karunanayake, R. K., Dissanayake, D. M. R. & Karunanayake, A. L. A study of snake bite among children presenting to a paediatric ward in the main Teaching Hospital of North Central Province of Sri Lanka. *BMC Res. Notes* **7**, 482 (2014).
Author contributions
A.K.M. conceived the idea, received funding, designed the experiments, interpreted data, and edited the final version of the manuscript. A.P. and B.K. performed the experiments, interpreted data and wrote the manuscript. M.V.K., N.C.S., and P.V.S. performed the in vivo pre-clinical studies with PAV, and approved the final version of the manuscript. A.K.M. conceived the idea, received funding, designed the experiments, interpreted data, and edited the final version of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-97501-2.

Correspondence and requests for materials should be addressed to A.K.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
